Preliminary results from a phase II clinical trial have provided the first evidence that treating people with kidney cancer with bevacizumab and erlotinib before surgery is safe, effective and may prolong patients’ survival, the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics heard on Thursday.
An international professional society has issued a patient?s bill of rights for the treatment of eating disorders, conditions that affect an estimated 30 million Americans, most of them young women. For 2 million, symptoms will progress to full-blown anorexia nervosa and approximately 10 percent will die from the disease. Treatment is often complex and typically involves not only the patient, but friends and family as well.
University of Illinois at Chicago researchers are comparing two drugs commonly used to treat attention deficit hyperactivity disorder to determine if genetic factors predict which children will respond to either or both drugs.
A Colorado-based company is launching a line of ‘medical- food’ products for the dietary management of asthma, eczema and other allergic conditions based on discoveries by Floyd H. ‘Ski’ Chilton, Ph.D., of Wake Forest University Health Sciences (WFUHS).
A new UCLA study has found that physicians discuss cost and aspects of obtaining newly prescribed medications only about one-third of the time during patient/doctor interactions.
For the first time, researchers have inhibited the development of epilepsy after a brain insult in animals. By using gene therapy to modify signaling pathways in the brain, neurology researchers found that they could significantly reduce the development of epileptic seizures in rats.
Scientists from King’s submitted a licence application yesterday (6 November) to the Human Fertilisation and Embryology Authority (HFEA) to allow them to fuse human cells with animal eggs. If granted, the licence will boost research into some of the most debilitating and untreatable neurological diseases.
DSM is continuing to build its personalised nutrition capabilities with its venturing arm making a ?2m investment in IntegraGen, and a collaboration with the French biotech to apply its genetic tests to weight management products.
Antiretroviral therapy can keep HIV infection in check and delay and ameliorate the symptoms of HIV/AIDS. However, the drugs do not manage to eradicate the virus completely; individuals have to stay on the drugs permanently. Preclinical studies in mice by Ekatarina Dadachova and colleagues (Albert Einstein College of Medicine) published in the international open-access journal PLoS Medicine now suggest a new strategy to locate and kill many if not all HIV-infected cells in the body.
Researchers at the University of Pennsylvania School of Medicine have discovered how the Kaposi’s sarcoma-associated herpesvirus (KSHV) subverts a normal cell process in order to promote tumor growth. The finding, published in the most recent issue of PLoS Pathogens, offers new potential strategies for treating Kaposi’s sarcoma and other cancers associated with viruses